Can an Old Tuberculosis Vaccine Help Control Type 1 Diabetes?

Type 1 diabetes is an autoimmune disease in which the body's immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. This leads to high blood sugar levels and a lifelong need for insulin treatment. Because Type 1 is fundamentally an immune system problem, researchers have been exploring whether therapies that can modify immune function might offer benefits.

One unexpected candidate is the BCG vaccine, a vaccine that has been used for nearly a century to protect against tuberculosis. Recent evidence suggests it might also have immune-modulating properties—meaning it could help calm down the overactive immune response seen in Type 1 diabetes.

Researchers at a single clinical center in Iran conducted a randomized, double-blind trial with 33 children who had Type 1 diabetes. The children were split into two groups matched by age and sex: one group received two doses of the BCG vaccine, administered four weeks apart, and the other group received a placebo injection.

The average age of participants was around 11 years old. The research team followed all participants for 18 months, collecting blood samples at the start and throughout the study period to measure blood sugar control and immune markers.

After 18 months, children in the BCG group showed a significant reduction in HbA1c levels compared to the control group. HbA1c is a measure of average blood sugar control over the previous 2–3 months, and lower levels indicate better long-term glucose management.

The study also found that anti-ICA antibodies—markers of immune system attack on beta cells—decreased in the BCG-vaccinated children by the end of the follow-up period. This suggests the vaccine may have influenced the autoimmune process.

Interestingly, there was no significant difference in fasting blood glucose levels between the two groups, meaning the benefit appeared to show up in long-term control rather than day-to-day fluctuations.

This was a small study with only 33 participants at a single center. To understand whether BCG truly helps in Type 1 diabetes, researchers would need to conduct larger trials in multiple centers, ideally across different countries and populations.

The exact biological mechanism—how or why BCG might reduce autoimmune attack on beta cells—is not yet clear. Further research is needed to understand what immune changes the vaccine triggers and whether those changes actually protect or restore beta cell function.

It is important to note that improved HbA1c does not mean the vaccine reverses or cures Type 1 diabetes. People with Type 1 still require insulin therapy and careful blood sugar management. This research explores whether BCG might be a complementary tool to improve control, not a replacement for established treatments.

The BCG vaccine has a long safety record, having been given to hundreds of millions of people worldwide. It has also been studied for other immune-related conditions beyond tuberculosis, which is why researchers thought it worth testing in Type 1 diabetes.

If further evidence supports these early findings, BCG could potentially become part of a multi-pronged approach to managing Type 1 diabetes—alongside insulin, glucose monitoring, and other therapies. However, any such application would require much larger and longer studies, as well as regulatory approval.

Source: Caspian journal of internal medicine. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.